|Bid||52.77 x 900|
|Ask||54.20 x 800|
|Day's Range||53.49 - 54.13|
|52 Week Range||47.88 - 66.16|
|Beta (5Y Monthly)||0.25|
|PE Ratio (TTM)||23.81|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 08, 2021|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for RDY
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE: RDY). The litigation concerns the submission by Dr. Reddy’s of an Abbreviated New Drug Application seeking approval to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets before the expiration of the Company’s U.S. patents. Related: Intercept Shares Jump After Reissuing Annual Guidance. Under the terms of the
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.